Publications by authors named "Praveen Kumar Tripathi"

Malaria morbidity has various presentations and the focus now shifts to uncommon signs and symptoms of malaria infection such as cognitive impairment to address the morbidity when the mortality declines. About 50% of children admitted to hospitals due to malaria experience neurological complications due to factors like low blood sugar, inflammation, elevated pressure, decreased oxygen levels, and excitotoxicity. Malaria during pregnancy negatively also impacts children's cognitive, behavioral, and executive function leading to neurodevelopmental delay due to increased susceptibility which can significantly affect maternal and child health, leading to higher rates of underestimated factors like anxiety, depression, and PTSD.

View Article and Find Full Text PDF
Article Synopsis
  • India accounted for a significant portion of the global malaria burden in 2021, with 79% of cases and 83% of related deaths in the South-East Asia Region, prompting the implementation of intensified malaria control programs supported by Global Funds.* -
  • A study is being conducted in 11 high malaria-endemic states, involving the assessment of malaria elimination interventions, healthcare system preparedness, and the attitudes of healthcare workers, involving interviews with nearly 38,000 households.* -
  • The findings of the study will be shared with ethical boards and the community, ensuring transparency, and will also be published in reputed journals, highlighting the local engagement through community outreach.*
View Article and Find Full Text PDF

Probiotic supplements are suggested to promote human health by preventing pathogen colonization. However, the mechanistic bases for their efficacy in vivo are largely uncharacterized. Here using metabolomics and bacterial genetics, we show that the human oral probiotic Streptococcus salivarius K12 (SAL) produces salivabactin, an antibiotic that effectively inhibits pathogenic Streptococcus pyogenes (GAS) in vitro and in mice.

View Article and Find Full Text PDF

Chikungunya virus (CHIKV) causes persistent arthritis and neurological problems imposing a huge burden globally. The present study aims to understand the interaction mechanism of Chikungunya virus and CHIKV-capsid in Huh7 cells. The RNA-sequencing and qRT-PCR method was used for the transcript and gene profiles of CHIKV virus and CHIKV capsid alone.

View Article and Find Full Text PDF

Capsids of several RNA viruses are reported to have unconventional roles attributed to their subcellular trafficking property. The capsid of CHIKV is also found to localize in the nucleus, but the rationale is not yet clear. To understand the role of the nuclear-localized capsid, we examined the nucleic acid binding and cargo delivery activity of the CHIKV capsid.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for effective therapies targeting the virus's main protease essential for its replication.
  • Researchers screened various clinically approved drugs in vitro for their ability to inhibit this protease, employing multiple methods including fluorescence quenching and surface plasmon resonance.
  • Teicoplanin was identified as the most effective inhibitor, showing significantly stronger activity against the protease compared to other drugs like lopinavir and hydroxychloroquine, which positions it as a promising therapeutic candidate for COVID-19.
View Article and Find Full Text PDF

Chikungunya has re-emerged as an epidemic with global distribution and high morbidity, necessitating the need for effective therapeutics. We utilized already approved drugs with a good safety profile used in other diseases for their new property of anti-chikungunya activity. It provides a base for a fast and efficient approach to bring a novel therapy from bench to bedside by the process of drug-repositioning.

View Article and Find Full Text PDF

Plasmodium falciparum leads to a virulent form of malaria. Progress has been achieved in understanding the mechanisms involved in the malarial infection, still there is no effective vaccine to prevent severe infection. An effective vaccine against malaria should be one which can induce immune responses against multiple epitopes in the context of predominantly occurring HLA alleles.

View Article and Find Full Text PDF

Chikungunya virus; the pathogen for chikungunya febrile and arthritic disease, having 11.8 kb positive-sense RNA genome encodes polyproteins for structural and non-structural regions. The polyprotein (P1234) corresponding to the non-structural part from 5' end gets auto-cleaved by the action of nsP2 protease, which leads to the generation of individual functional enzymatic proteins like nsP4, nsP1, nsP2 and nsP3.

View Article and Find Full Text PDF

Objectives: Parasitic infections such as toxoplasmosis, hydatidosis, and cysticercosis infect a large population worldwide. in the pancreas could damage the pancreatic cells. Hence, insulin secretion would be affected which leads to increased risk of diabetes.

View Article and Find Full Text PDF

Context: T-cell hypo-responsiveness in microfilaria (Mf) carriers against the microfilarial stage antigen of has been described, but no study has been carried out to assess antibody dynamics against stage-specific antigens.

Aim: The work was carried out with the aim to assess stage-specific antibody responses against L3 and microfilarial stage antigens in brugian filariasis in an endemic area.

Setting And Design: Patients with different clinical spectra of brugian filariasis were recruited to evaluate antibody responses to brugian antigens.

View Article and Find Full Text PDF

Human lymphatic filariasis (LF) is a major cause of disability globally. The success of global elimination programmes for LF depends upon effectiveness of tools for diagnosis and treatment. In this study on stage-specific antigen detection in brugian filariasis, L3, adult worm (AW) and microfilarial antigenaemia were detected in around 90-95% of microfilariae carriers (MF group), 50-70% of adenolymphangitis (ADL) patients, 10-25% of chronic pathology (CP) patients and 10-15% of endemic normal (EN) controls.

View Article and Find Full Text PDF